retatrutide and heart issues side effects: what the trials show how to manage them Retatrutide Severe Obesity Trial Shows
Description
K., Perry, R., Wider, B., & Ernst, E
In patients with T2DM who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) agonists are used as adjunct or alternative therapies given their dual benefits for insulin sensitivity and weight loss
Nutritionists play a crucial role in the success of GLP-1 therapy by ensuring adequate nutrition during rapid weight loss, managing side effects, and promoting sustainable eating habits
Adverse effects are generally limited to gastrointestinal disturbances, which can be managed through dose reduction and caution around anaesthesia
Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, et al
